



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT  
FIRST QUARTER OF 2020 (2020Q1)**

**Substance Abuse Epidemiology Section  
Prescription Drug Overdose Prevention Program  
Injury and Behavioral Epidemiology Bureau  
Epidemiology and Response Division**



This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.




Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.

## I. New Mexico Prescription Monitoring Program (PMP) Measures



## I. New Mexico Prescription Monitoring Program (PMP) Measures



## I. New Mexico Prescription Monitoring Program (PMP) Measures

### Totals

Year and Quarter	2019Q1	2019Q4	2020Q1	Quarterly % Change 2019Q4 vs 2020Q1	Quarterly % Change 2019Q1 vs 2020Q1
Total number of controlled substance patients	234,193	215,810	217,897	1.0%	-7.0%
Number of patients receiving opioids	153,396	136,180	137,161	0.7%	-10.6%
Number of opioid prescriptions filled (excluding buprenorphine/naloxone)	323,222	292,045	294,759	0.9%	-8.8%
Number of buprenorphine/naloxone prescriptions filled	23,628	25,311	26,566	5.0%	12.4%
Number of high dose (>=90 MME/day) opioid prescriptions excluding buprenorphine/naloxone	35,002	31,794	30,771	-3.2%	-12.1%
Total MME of opioids filled - excluding buprenorphine/naloxone	274,456,795	256,344,625	255,064,917	-0.5%	-7.1%
Total MME/prescription-day	55	56	56	0.6%	1.5%
Number of patients receiving benzodiazepines	82,765	76,702	76,705	0.0%	-7.3%
Number of benzodiazepine prescriptions filled	182,677	169,974	172,675	1.6%	-5.5%
Number of high-dose(>=40 DME/day) benzodiazepine prescriptions filled	31,522	28,999	29,105	0.4%	-7.7%
Total DME of benzodiazepines filled	94,408,678	86,152,616	87,022,566	1.0%	-7.8%
Total DME/patient	1,141	1,123	1,135	1.0%	-0.5%

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MME = Morphine Milligram Equivalent; reference at [http://www.cdc.gov/drugoverdose/pdf/calculating\\_total\\_daily\\_dose-a.pdf](http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf)

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

## I. New Mexico Prescription Monitoring Program (PMP) Measures

### Number of Patients with:

Year and Quarter	2019Q1	2019Q4	2020Q1	Quarterly % Change 2019Q4 vs 2020Q1	Quarterly % Change 2019Q1 vs 2020Q1
High dose opioids (>=90 MME/day)	12,319	11,058	10,597	-4.2%	-14.0%
High dose benzodiazepines (>=40 DME/day)	13,824	12,652	12,505	-1.2%	-9.5%
Opioids >=90 days and <90% of days in past 6 months	18,479	16,752	16,350	-2.4%	-11.5%
Opioids >=90% of days in past 6 months	30,080	28,580	28,471	-0.4%	-5.3%
Benzodiazepines >=90 days and <90% of days in past 6 months	21,262	19,269	18,847	-2.2%	-11.4%
Benzodiazepines >=90% of days in past 6 months	23,619	22,246	22,250	0.0%	-5.8%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	3,374	2,619	2,562	-2.2%	-24.1%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	2,097	1,699	1,674	-1.5%	-20.2%
Concurrent opioid and benzodiazepines (>=10 days overlap)	17,000	14,454	14,013	-3.1%	-17.6%
High dose opioids (>=90 MME/day) plus benzodiazepines	3,135	2,551	2,447	-4.1%	-21.9%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	2,269	1,916	1,808	-5.6%	-20.3%
New Opioid Patients with at least 30 days of coverage in the past 3 months	2,803	2,459	2,344	-4.7%	-16.4%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	4,151	3,363	3,664	9.0%	-11.7%

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

## I. New Mexico Prescription Monitoring Program (PMP) Measures


### New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2019Q1	2019Q4	2020Q1	Quarterly % Change 2019Q4 vs 2020Q1	Quarterly % Change 2019Q1 vs 2020Q1
Total active controlled substance prescribers	3,213	3,037	3,061	0.8%	-4.7%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	60	58	60	3.4%	0.0%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	137	123	115	-6.5%	-16.1%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	9	8	8	0.0%	-11.1%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,463	1,596	1,661	4.1%	13.5%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	469	290	276	-4.8%	-41.2%
Number of Patients with PMP reports requested by practitioners	169,107	240,720	256,221	6.4%	51.5%
% of Chronic opioid users with a PMP request in the past 3 months*	74.7%	79.1%	80.5%	1.7%	7.7%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	51.6%	56.8%	59.1%	4.0%	14.6%
% of New Opioid Patients with a PMP request in the past 3 months**	24.9%	32.9%	33.9%	3.3%	36.2%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	29.9%	37.8%	39.4%	4.4%	32.0%

\*Chronic users are those with at least 90 days of coverage in six months.

\*\*New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



## II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone) Measures

Year and Quarter	2019Q1	2019Q4	2020Q1	Quarterly % Change 2019Q4 vs 2020Q1	Quarterly % Change 2019Q1 vs 2020Q1
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	189	214	211	-1.4%	11.6%
Buprenorphine/naloxone patients (>=10 days)	6,282	6,853	7,099	3.6%	13.0%
Buprenorphine/naloxone prescriptions filled	23,628	25,311	26,566	5.0%	12.4%
Total Practitioners with DATA Waiver	650	826	899	8.8%	38.3%
Nurse Practitioners and PA's with DATA Waiver	174	257	283	10.1%	62.6%

### Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	5,541	6,314	6,443	2.0%	16.3%
Number of distinct NM Medicaid providers of methadone	12	11	11	0.0%	-8.3%

Methadone Treatment Programs by Survey Date	Mar 2019	Dec 2019	Mar 2020		
Number of Methadone Treatment Programs	17	17	17	0.0%	0.0%
Number of Methadone Treatment Patients in those Programs	6,696	6,957	7,811	12.3%	16.7%


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine/naloxone data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



### III. Naloxone Distribution and Usage Measures

Year and Quarter	2019Q1	2019Q4	2020Q1	Quarterly % Change 2019Q4 vs 2020Q1	Quarterly % Change 2019Q1 vs 2020Q1
New Enrollments in NM State Government Naloxone Programs	3,060	2,733	2,205	-19.3%	-27.9%
Total Number of NM Naloxone Doses distributed	11,320	13,036	11,952	-8.3%	5.6%
Total Number of NM Reported Reversals	1,067	1,057	856	-19.0%	-19.8%

Year and Quarter	2019Q1	2019Q4	2020Q1	Quarterly % Change 2019Q4 vs 2020Q1	Quarterly % Change 2019Q1 vs 2020Q1
Pharmacies Presenting Medicaid Naloxone Claims	234	251	249	-0.8%	6.4%
Number of Medicaid Naloxone Claims Processed	1,716	4,226	5,262	24.5%	206.6%

Some naloxone doses were given to organizations and may not have been distributed in that quarter.

Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 286 outpatient Pharmacies with a NM address in 2019 according to the Board of Pharmacy.

All law enforcement agencies have been contacted about naloxone training and use. The data reported reflect the number of agencies where at least some officers are carrying naloxone.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

